Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981796 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
A Phase 3 study of Neoplasms, sponsored by Tesaro.
- Active
- Registry status
- Phase 3
- Development phase
- 785
- Enrollment target
- 20
- Study locations
NCT03981796: Active Phase 3 study of Neoplasms, sponsored by Tesaro.
NCT03981796 is a Phase 3 study of Neoplasms that is active but no longer recruiting, run by Tesaro. The registered enrollment target is 785 participants, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03981796, a Phase 3 study of Neoplasms, is active but no longer recruiting, sponsored by Tesaro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 785 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Niraparib
- BIOLOGICAL Dostarlimab
- DRUG Placebo matching dostarlimab
Study Locations (20)
Florida
- GSK Investigational Site - Deerfield Beach
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Scottsdale
- GSK Investigational Site - Tucson
- GSK Investigational Site - Tucson
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Augusta
- GSK Investigational Site - Savannah
Indiana
- GSK Investigational Site - Fort Wayne
- GSK Investigational Site - Indianapolis
- GSK Investigational Site - Indianapolis
California
- GSK Investigational Site - Newport Beach
- GSK Investigational Site - Palo Alto
Illinois
- GSK Investigational Site - Hinsdale
- GSK Investigational Site - Zion
Iowa
- GSK Investigational Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 785 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2026-11-26 |
| Phase | Phase 3 |
What the registry record for NCT03981796 still lists
NCT03981796 is an interventional study that assigns participants to a tested intervention. The registered 785 participants enrollment target is mid-sized for trials with a published cap, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03981796 names 20 study sites across 7 states, led by Florida, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT03981796 about?
NCT03981796 is a clinical study titled "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer". This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel follow...
What is the current status of trial NCT03981796?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 785 participants. The study started on 2019-07-18. Estimated completion is 2026-11-26.
What conditions does trial NCT03981796 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03981796?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Niraparib (DRUG), Dostarlimab (BIOLOGICAL), Placebo matching dostarlimab (DRUG).
Who is sponsoring clinical trial NCT03981796?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981796 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03981796's enrollment target sits among peer trials
785 17th of 158 higher than 142 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
COMPLETED · Phase 3
-
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
COMPLETED · Phase 3
-
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- NCT07359846 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI